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Clinical immunotherapy trials like dendritic cell-based vaccinations are hampered by the tumor’s oﬀensive repertoire that
suppresses the incoming eﬀector cells. Regulatory T cells are instrumental in suppressing the function of cytotoxic T cells. We
studied the eﬀect of low-dose cyclophosphamide on the suppressive function of regulatory T cells and investigated if the success
rate of dendritic cell immunotherapy could be improved. For this, mesothelioma tumor-bearing mice were treated with dendritic
cell-based immunotherapy alone or in combination with low-dose of cyclophosphamide. Proportions of regulatory T cells and
the cytotoxic T cell functions at diﬀerent stages of disease were analyzed. We found that low-dose cyclophosphamide induced
beneﬁcial immunomodulatory eﬀects by preventing the induction of Tregs, and as a consequence, cytotoxic T cell function was
no longer aﬀected. Addition of cyclophosphamide improved immunotherapy leading to an increased median and overall survival.
Future studies are needed to address the usefulness of this combination treatment for mesothelioma patients.
1.Introduction
Malignant mesothelioma (MM) is a cancer arising from
mesothelial cells that lines the body’s serous cavities (pleural,
pericardial, and peritoneal) and the internal organs and
is characterized by poor prognosis [1]. Chemotherapy or
surgical treatments result in only limited improvements
in response and survival. Novel therapeutic strategies are
therefore needed. Immunotherapy is a promising but also
challenging approach in the treatment of cancer.
Dendritic cells (DCs) are highly mobile antigen-
presenting cells, capable of instructing and controlling the
activation of NK cells, NKT cells, and B and T lymphocytes
[2–4]. Previously we showed that DC-based immunotherapy
in a murine MM model leads to protective immunity as
well as regression of established tumors [5]. Currently we
are investigating DC-based immunotherapy in MM patients.
Although DC-vaccines are well tolerated by patients, further
optimization is necessary to exploit the full potential of this
therapeutic strategy [6].
It is becoming evident that immune suppression plays
a crucial role in tumor progressing. Tumors secrete several
mediators to recruit and/or activate suppressive cells. Regu-
latory T cells (Tregs) are prominent cells in this suppressive
environment. These cells are instrumental in allowing a
growing cancer to evade immunological attack by impairing
Tc e l lf u n c t i o n[ 7]. Elevated levels of Tregs have been
reported in many tumors and their presence predicts for
poorsurvival.Wehavedemonstratedpreviouslythepresence
of Tregs within the tumors of MM patients [8]. It has also
been described that Tregs are increased in the peripheral
blood [9] and pleural eﬀusions [10] of these patients.
Recent clinical studies have shown that low-dose
cyclophosphamide (CTX) induces beneﬁcial immunomod-
ulatory eﬀects in the context of active or adoptive
immunotherapy[11–21].CTXiswidelyusedtotreatvarious
types of malignancies and some autoimmune disorders. It
displays either immunosuppressive or immunopotentiating
eﬀects, depending on the dosage and the timing of drug
administration [22]. Although the mechanisms underlying2 Journal of Biomedicine and Biotechnology
these modulations are not fully understood, low-dose CTX
might prevent the development and functionality of the
Tregs [23–27].
VanderMostetal.reportedthatCTXenhancestheeﬀec-
tiveness of gemcitabine treatment in murine mesothelioma
by reducing the amount of Tregs [28, 29]. Thereby they
underline the immunogenic role of Tregs in the suppression
of activated target cells. On the other hand, Jackaman et
al. recently stated that Tregs are no potent regulators of
antimesothelioma immunity in their murine model and that
targeting of these cells will not improve results [30]. Taken
together, the role of Tregs in mesothelioma is controversial
and whether these cells will inﬂuence the outcome of
immunotherapy is still unclear.
Here we investigated the eﬀect of CTX on immuno-
suppression and the combination of CTX and DC-based
immunotherapy was studied in a murine MM model.
We found that CTX reduced the levels of Tregs and
this induced beneﬁcial immunomodulatory eﬀects in the
context of DC-based immunotherapy. These results antic-
ipate that antitumor immune responses elicited by DC-
based immunotherapy in humans might be improved by
simultaneously depleting Tregs using low-dose CTX.
2. Methods
2.1. Animals and Cell Lines. Female 6–10 week old BALB/c
(H-2d) mice (Harlan, Zeist, The Netherlands) were housed
under pathogen-free conditions at the animal care facility
of the Erasmus MC, Rotterdam. Experiments were approved
by the local Ethical Committee for Animal Welfare and
complied to the Guidelines for the Welfare of Animals in
Experimental Neoplasia by the United Kingdom Coordi-
nating Committee on Cancer Research (UKCCCR) and by
the Code of Practice of the Dutch Veterinarian Inspection.
The AB1 cell line, a mouse mesothelioma cell line, was
kindly provided by Professor Bruce W.S. Robinson of the
Queen Elizabeth II Medical Centre, Nedlands, Australia. The
cell line was derived from tumors induced by Wittenoom
Gorge crocidolite asbestos injected intraperitoneally into a
BALB/c mouse [31]. Cells were cultured in RPMI 1640
medium containing 25mM HEPES, Glutamax, 50μg/ml
gentamicin, and 5% (v/v) fetal bovine serum (FBS) (all
obtained from GIBCO/Invitrogen, Breda, The Netherlands)
in a humidiﬁed atmosphere at 37
◦C and 5% CO2,i na i r .A B 1
c e l l sw e r ep a s s a g e do n c eo rt w i c eaw e e kt oan e wﬂ a s kb y
treatment with 0.05% trypsin, 0.53mM EDTA in phosphate
buﬀered saline (PBS, all GIBCO/Invitrogen). The cell line
was regularly tested and remained negative for mycoplasma
contamination.
2.2. Reagents. Cyclophosphamide ([CTX], the generic name
for Endoxan) was purchased from Baxter B.V., Utrecht, The
Netherlands. A stock solution was prepared by dissolving 1
gram into 50ml of PBS. It was further diluted in drinking
water at a concentration of 0.13mg/ml.
Every 4 days bottles were carefully examined (volume
was determined) and replaced with fresh bottles containing
100ml of drinking water or CTX-containing water. No
changes in the drinking pattern of mice were observed
between tumor-bearing mice with normal water or with
CTX-containing drinking water (+/−3ml per day per
mouse). This equals approximately 20mg CTX/kg body
weight/day and is considered as a low-dose. Dehydration,
being one of the points for signs of illness, was routinely
checked. No signs of dehydration were observed during
experiments except for a few cases with ill health or overt
tumor growth.
2.3. Source of Tumor Antigen Derived from AB1 Tumor. AB1
cell line-derived tumor lysate was prepared from 50 × 106
cells suspended per ml PBS. The cell suspension was frozen
in liquid nitrogen and disrupted by four cycles of freeze-
thawing followed by sonication for 4 × 10 seconds with an
amplitude of 10 microns, using a Soniprep 150 ultrasonic
disintegrator equipped with a microtip (Sanyo Gallenkamp
BV, Breda, The Netherlands) on ice. Cell lysate was aliquoted
a n ds t o r e da t−80
◦C.
2.4. Culture Conditions of Bone Marrow-Derived DC Used
for Vaccination. DCs were generated with only minor adap-
tations from a previously described protocol by Lutz [32].
After ﬂushing femurs and tibias and red blood cell lysis,
resulting bone marrow cells (2 × 106) were seeded in 100-
mm Petri dishes (day 0) and cultured in 10ml DC Cul-
ture Medium [DC-CM]: RPMI 1640 containing glutamax-
I (GIBCO/Invitrogen) supplemented with 5% (v/v) FBS,
50μM β-mercaptoethanol (Sigma-Aldrich), 50μg/ml gen-
tamicin (Invitrogen), and 20ng/ml recombinant murine
granulocyte macrophage-colony-stimulating factor [GM-
CSF, kindly provided by Professor K. Thielemans, Free
University Brussels, Belgium]. Cells were cultured at 37
◦C
in a humidiﬁed atmosphere at 5% CO2 ,i na i r .A td a y
3, 10ml of fresh DC-CM was added. On day 6, 10ml of
each plate was replaced with 10ml of fresh DC-CM. After
8 days of culture, AB1 cell lysate was added to the DC
cultures, to the equivalent of three AB1 cell-equivalents per
DC. After 8 hours, 100μg/ml LPS (E. coli 026:B6, Sigma-
Aldrich) was added to the culture to allow complete matu-
ration while incubated overnight. The next day, DCs were
harvested by gentle pipetting and puriﬁed by Lympholyte-
Mammal(Cedarlane,Hornby,ON,Canada)densitygradient
centrifugation, the interphase washed three times in PBS and
resuspendedataconcentrationof1×106 viablecellsin500μl
PBS. The quality of the DC preparation was determined by
cell-counting, morphologic analysis and cell surface marker
expression by ﬂow cytometry, as previously described [5].
DCs (1 × 106) were delivered into the peritoneal cavity of
BALB/c mice; control mice received 500μl PBS.
2.5. Treatment with Tumor Lysate-Pulsed DCs and Cyclophos-
phamide on Outcome. Initial experiments were performed
to determine the optimal concentration of CTX necessary
to reduce Tregs in vivo. Continuous administration via
the drinking water of low concentrations (“metronomic”)
CTX had our preference because a single administrationJournal of Biomedicine and Biotechnology 3
of a higher dose or multiple administrations i.p. engenders
worse life expectancy as a consequence of peritoneal damage
caused by the needle. Approximately 20mg CTX/kg body
weight/day in the drinking water of mice was the optimal
concentration for further studies in mice, concentrations
below 100mg/kg are considered as a low dose. No eﬀect on
feeding, body weight, and physical well-being or other side
eﬀects were observed at this concentration.
On day 0, BALB/c mice (4 groups each consisting of 6
mice) were inoculated intraperitoneally with 0.5 × 106 AB1
tumor cells in 500μl PBS. On day 12, 12 mice (2 groups)
were vaccinated with 1 × 106 LPS-matured DCs pulsed with
AB1 tumor cell line lysate in 500μl PBS. From day 3 till day
10 and/or day 14 till day 21 mice were given drinking water
supplemented with 0.13mg/ml CTX. Mice were examined
daily for evidence of ill health or overt tumor growth.
Mice were killed if profoundly ill, according to UKCCCR
regulations, and were scored as a death in survival analysis.
All mice underwent extensive autopsy.
2.6. Immunohistology on Tumor Biopsies. Tumor biopsies
were embedded in Tissue-Tek II optimum cutting temper-
ature medium (Miles, Naperville, IL, USA), snap-frozen,
a n ds t o r e da t−80
◦C. Tissue sections (6μm) were cut on
an HM-560 cryostat (Microm, Heidelberg, Germany) and
immunostaining was carried out using a rat antimouse
Foxp3 antibody (eBioscience [#14-5773], San Diego, CA,
USA). Binding of antibody was detected using alkaline
phosphatase- (AP-) conjugated goat antirat (Sigma-Aldrich
Chemie B.V.). Naphtol-AS-MX-phosphate (0.30mg·mL−1;
Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands)
and new fuchsine (160mg·mL−1 in 2MHCl; Chroma-
Gesellschaft, K¨ ongen, Germany) were used as substrate.
The speciﬁcity was checked using a protein concentration-
matched nonrelevant rat antibody and PBS. Double staining
of Foxp3 and CD8 was performed using the AP-conjugated
goat antirat followed by rabbit antiphycoerythrin (AbD
Serotec, D¨ usseldorf, Germany) followed by incubation with
horseradishperoxidase-(HRP-)conjugatedswineantirabbit.
Naphtol-AS-MX-phosphate and 1mM Fast Blue substrate
were used as substrate for AP, and NovaRed was used as sub-
strate for HRP, according to the manufacturer’s instructions
(Vector, Burlingame, CA, USA). Foxp3 and phycoerythrin-
labeled antimouse CD8 (BD Biosciences, San Jose, CA, USA)
were both used at a dilution of 1:10. Signals were captured
on a Leica microscope (Leica Microsystems B.V., Rijswijk,
The Netherlands).
2.7. Preparation of Lymphocytes from Lymphoid Organs or
Blood. Lymphocytes were collected from the spleens, lymph
nodes, and blood of mice from each group. Brieﬂy, spleens
and lymph nodes were aseptically removed and mechanically
dispersed in cold PBS. Cells suspensions were ﬁltered
through a 100μm nylon mesh cell strainer (BD Biosciences,
Bedford, MA, USA). Resulting suspensions and blood were
depleted of erythrocytes by density gradient centrifugation,
washed twice with PBS +2% BSA, and resuspended at a
concentrationof1×106 cells/mlforﬂowcytometricanalysis.
2.8. Flow Cytometry. The following antimouse antibodies
were used: ﬂuorescein isothiocyanate- (FITC-) conjugated
anti-CD4 (1:800), anti-CD19 (1:200), phycoerythrin- (PE-
)-conjugated anti-CD3 (1:25), anti-CD25 (1:200) (all
from BD Biosciences), allophycocyanin- (APC)conjugated
anti-Foxp3 (1:25) (eBioscience), and appropriate isotype-
matched controls.
For cell surface marker staining, cells were washed with
FACS-wash (0.05% NaN3, 2% BSA in PBS) and Fcγ II/III
receptor blocking was performed using antimouse 2.4G2
antibody (1:100; kindly provided by L. Boon, Bioceros,
Utrecht, The Netherlands) for 15 minutes on ice. After
the blocking procedure, properly diluted antibodies for cell
surface staining were added into each sample and placed on
ice for 30 minutes protected from light. After two additional
washes with FACS-wash, Fix/Perm buﬀer (eBiosience) was
added and cells were incubated for 1 hour at 4◦Ci nt h e
dark. Cells were washed twice with Perm buﬀer. Intracel-
lular staining was performed for Foxp3 according to the
manufacturer’s instructions (eBioscience). After blocking for
15 minutes with blocking antibody 2.4G2, properly diluted
APC-conjugated Foxp3 antibody in Perm buﬀer was added
and incubated for 30 minutes on ice protected from light.
After washing the cells twice with Perm buﬀer, cells were
washedwithFACS-washandmeasured.Dataacquisitionwas
performed by ﬂow cytometry (LSR II; BD Biosciences) and
data analysis was performed with FlowJo software (Tree Star,
Inc.).
2.9. Coculture of Tregs and Activated Splenocytes. Splenocytes
obtained from tumor-bearing mice were stained for CD3,
CD4, CD8, and CD25. Four colour sample sorting was done
on a FACS ARIA (BD Biosciences). Tregs were deﬁned as
CD3+CD4+CD25+bright cells and sorted with a purity >90%
as determined by intracellular staining on Foxp3 expression.
Splenocytes of DC-treated mice were cocultured with sorted
Treg cells at diﬀerent ratios. Splenocytes were restimulated
for 4 hours using anti-CD3 and stained with mAbs directed
against CD3, CD8, intracellular Granzyme B, and IFN-γ.
2.10. Statistical Analysis. Data are expressed as mean ± SD.
Comparisons between groups were made using the Mann-
Whitney U-test for independent samples. A two-tailed P-
value <. 05 was considered signiﬁcant. Data presented as
a percentage of tumor-free animals were analyzed with
Kaplan-Meier survival curves, using the log-rank test to
determine statistical signiﬁcance.
3. Results
3.1. Regulatory T Cells in the Mouse Mesothelioma Model.
The mesothelioma mouse model described in our pre-
vious study was used to examine the presence of
CD4+CD25+Foxp3+ T cells in tumor progression [8].
In this protocol, BALB/c mice were intraperitoneally (i.p.)
injected with a lethal dose of 0.5 × 106 AB1 tumor cells
or 500μl PBS as control. First signs of terminal illness
(typically formation of ascites, ruﬄed hair, or marked loss of4 Journal of Biomedicine and Biotechnology
condition) appeared between 20 days and 30 days in tumor
cell inoculated mice. Mice were sacriﬁced and subjected to
extensive autopsy. All tumor inoculated mice showed solid
tumor formation within the peritoneal cavity. The nature
of these solid tumors varied from small nodules spreading
throughout the mesentery and peritoneal lining to a single
large mass. Tumor tissue, blood, spleen, and lymph nodes
were collected from tumor-bearing mice for further analyses
at day 10 or at ﬁrst signs of terminal illness. No tissue
abnormalities or formation of tumors could be detected in
naive (PBS treated) mice.
The presence of Tregs in mesothelioma tissue sections
at day 10 was analyzed by immunohistochemistry for the
phenotypic evidence of the transcription factor Foxp3, a
hallmark of naturally arising CD4+CD25+ Treg cells [33–
37]. Stainings conﬁrmed that mouse tumor tissue obtained
from AB1 inoculated mice contained signiﬁcant amounts
of Foxp3+ regulatory T cells, consisting with previous ﬁnd-
ings in human mesothelioma tissue [8]. Foxp3-expressing
cells were located in the proximity of the tumor areas
(Figure 1(a)). Double staining showed that the presence
of these cells was occasionally in the vicinity of CD8+T
cells, suggesting their possible direct suppressive role in
antitumoral responses (Figure 1(b)).
We then examined the blood and peripheral lymphoid
organs for the presence of Tregs, determined by CD4, CD25,
and Foxp3 positive expression using ﬂow cytometry. In
peripheral blood of control mice, the mean proportion
of Treg cells was 4.9% of all CD4+ T cells. The percent-
age increased in the blood to 6.1% ten days after the
inoculation of AB1 tumor cells (Figure 1(c)). Also the
CD4+CD25+Foxp3+ Tregswereincreasedinthelymphnodes
from 8.9% to 11.5% of the total CD4+ Tc e l lp o p u l a t i o n
in tumor-bearing mice (Figure 1(d)). In the splenocytes
from tumor-inoculated mice, the presence of Foxp3+ Tregs
increased to 11% compared to 9% in the control group
treated with PBS alone (data not shown).
To determine the impact of a growing tumor on Tregs,
the percentage of Foxp3+ T cells in the draining lymph
nodes was measured. Total weight of excised tumor tissue
and the percentage of Tregs in the draining lymph nodes of
corresponding mice are depicted in Figure 1(e).A tt e nd a y s
after AB1 inoculation (n = 5), the weight of the total tumor
mass collected varied from 0.1 gram to 1 gram, or larger (1.5
to2.1gram)whenmiceshowedevidenceofillhealthorovert
tumor growth (n = 3).
In conclusion, Tregs were found within the tumor area
and increased proportions of Tregs were found in the tumor-
bearing mice. Moreover we show a signiﬁcant increase in the
proportion of Tregs that correlates with tumor burden (P =
.0039).
3.2. Reduction of Tregs Improves Cytotoxic T Cell Function
In Vivo. To demonstrate that cytotoxic T cell function is
inhibited by Tregs, the intracellular expression of granzyme
Ba n dI F N - γ in activated CD8+ Tc e l l sw a sm e a s u r e d .
Tregs from tumor-bearing mice were isolated from spleen.
These CD4+CD25+ T cells were then added in diﬀerent
ratios to the activated splenocytes isolated from DC-treated
mice. Intracellular granzyme B expression by CD8+ Tc e l l s
decreased in the fractions containing high amounts of
CD4+CD25+ T cells. The same was observed for the IFN-γ
expression (Figure 2). When CD4+CD25+ T cells are present
in a ratio higher than 1:100, the function of CD8+ Tc e l li s
impaired.
Taken together, these data provide evidence that the
addition of Tregs leads to impaired CD8 T cell activation.
3.3. Eﬀects of Low-Dose Cyclophosphamide on the T and B Cell
Populations. To examine the immunomodulating eﬀects of
CTX on Tregs, BALB/c mice were inoculated i.p. with 0.5 ×
106 AB1 mesothelioma tumor cells and given drinking water
with or without CTX. After 10 days peripheral blood and
spleen were analyzed. Metronomic CTX treatment resulted
in a signiﬁcant decrease in the proportions of CD19+ Bc e l l s
and an increase of CD3+ T cells (Figures 3(a) and 3(b)), in
agreement with reports by others [13]. In contrast to the
signiﬁcant increase in the proportions of total CD3+ T cells,
weobservedasigniﬁcantreductioninthefractionsofFoxp3+
T cells (Figures 3(a) and 3(b)).
In summary, these data show that metronomic adminis-
tration of low-dose CTX has a strong immune-modulating
eﬀect in vivo, causing a shift in ratio between CD19+/CD3+
cells. Addition of CTX to drinking water of mice leads to a
signiﬁcant increase in the proportion of CD3+ T cells in the
peripheral blood and the spleen, whereas the proportion of
Tregs is reduced.
3.4. CTX Improves Suboptimal Dc-Based Immunotherapy.
Next, we then investigated if combining CTX and DC
vaccination enhanced the eﬃcacy of the DC treatment as an
antitumor treatment. In contrast to optimal DC-treatment
protocols (as described by Hegmans et al. [5]), DCs are given
at a relative late time point (day 12) in order to achieve
suboptimal survival of DC-treated mice. Twelve days after
i.p. tumorcellinoculation, micewerevaccinatedwith1×106
LPS-matured DCs pulsed with AB1 tumor lysate. Mice that
received CTX had an increased survival, as seen in our earlier
experiments, compared to untreated mice.
When mice were given drinking water supplemented
with 0.13mg/ml CTX from day 3 till day 10 and day 14 till
day 21, an increased survival was measured. However, the
combination of DC-based immunotherapy and CTX admin-
istration signiﬁcantly improved survival compared to DC-
based immunotherapy (P<. 0035) or CTX administration
alone (P<. 0056) (Figure 4).
Therefore, we conclude that CTX is a powerful tool to
optimize suboptimal DC-based immunotherapy. Although
CTX alone also improves survival, the combination of both
was signiﬁcantly better.
3.5. Long-Term Administration of CTX Improves Survival
Compared to Pre- or Postlmmunotherapy Treatment. It has
been reported that the timing of CTX administration is
critical [38, 39], therefore we investigated the consequences
of administration at diﬀerent time points. To evaluate the
eﬀect of timing of CTX administration, mice were dividedJournal of Biomedicine and Biotechnology 5
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Figure 1: Increase in the proportion of regulatory T cells in a murine model for mesothelioma. (a) Left: The transcription factor Foxp3, a
hallmarkofnaturallyarisingCD4+CD25+ Tregs,wasexpressedinsidethetumor(redstaining).Cellswerecounterstainedwithhaematoxylin.
[Magniﬁcation 200×] Right: A higher magniﬁcation (400×) shows the appearance of Foxp3+ cells as indicated by arrows. (b) Tregs (blue
staining) were occasionally present in the near vicinity of CD8+ cells (red staining) [Magniﬁcation 1000×]. (c) and (d) Percentage of Tregs
(deﬁned as CD4+CD25+Foxp3+ cells) from total CD4+ T cells in the peripheral blood and draining lymph nodes is signiﬁcantly higher at
day 10 in tumor-bearing mice compared to healthy mice as observed by ﬂow cytometry. (e) A positive correlation was found between the
total tumor weight and the percentage of Tregs, measured in the lymph nodes of tumor-bearing mice. Five mice were euthanized at day 10
(tumor weight varied from 0.1 gram to 1 gram) and three mice at stage with ill health (tumor weight 1.5 to 2.1 gram). Correlation coeﬃcient
of the trend line (R-squared) is 0.780 (P value is .0039).6 Journal of Biomedicine and Biotechnology
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Figure 2: Tregs inhibit CTL function in vitro. (a) Activated splenocytes from DC-treated mice were cocultured with CD4+CD25+Foxp3+
cells (puriﬁed from tumor-bearing mice) in diﬀerent ratios. The percentage of intracellular IFN-γ of CD8+ cells was measured using ﬂow
cytometry. And (b) the percentage of intracellular IFN-γ and granzyme B expression was measured using FACS. A reduction in the IFN-γ
and granzyme B expression was found especially in those fractions where increasing doses of Treg were added to the CD8+ Tc e l l s .
0
30
40
50
60
C
D
1
9
+
c
e
l
l
s
(
%
)
∗
Untreated CTX
0
35
45
55
C
D
3
+
c
e
l
l
s
(
%
)
Untreated CTX
∗
0
5
6
7
F
o
x
P
3
+
C
D
4
+
T
c
e
l
l
s
(
%
)
Untreated CTX
(a) Peripheral blood
0
5
10
15
20
25
C
D
1
9
+
c
e
l
l
s
(
%
)
∗
Untreated CTX
0
65
75
85
C
D
3
+
c
e
l
l
s
(
%
)
Untreated CTX
∗
0
9
10
11
12
13
F
o
x
P
3
+
C
D
4
+
T
c
e
l
l
s
(
%
)
Untreated CTX
∗
(b) Spleen
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CD19+ cells was signiﬁcantly decreased (P<. 05) in CTX-treated tumor-bearing mice. CD3+ cells were signiﬁcantly increased (P = .0325)
in the peripheral blood of CTX-treated tumor-bearing mice compared to untreated tumor-bearing mice. (b) CD19+ cells were signiﬁcantly
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Figure 4:CTXcombinedwithDC-basedimmunotherapyprolongs
survival. Kaplan-Meier survival plot showing the eﬀect of the
combination of CTX and DC-based immunotherapy. Mice were
given drinking water supplemented with 0.13mg/ml CTX from
day 3 till day 10 and day 14 till day 21. Tumor-lysate-pulsed DCs
were given at day 12. Survival signiﬁcantly improved when CTX
and DC-based immunotherapy were combined compared to DC-
based immunotherapy (P = .0035) or CTX administration alone
(P = .0056). Each group contained 8 mice.
into three groups, receiving low-dose CTX before (day 3
till 10) or after (day 14 till 21) immunotherapy or long-
term CTX (day 3 till 10 and day 14 till 21). Mice were
treated with DC-immunotherapy on day 12. No signiﬁcant
diﬀerences were found between the groups (before [P =
.37] , after treatment [P = .84]). However long-term CTX
administration may prolong the survival beneﬁcial since no
side eﬀects of this low dose were observed (Figure 5).
4. Discussion
Cancer immunotherapy attempts to harness the exquisite
power and speciﬁcity of the immune system to recognize
and destroy tumor cells or to prevent tumor recurrence.
The ﬁnding that some patients with malignant pleural
mesothelioma(MM)havetumorsthatregressspontaneously
[40–43] or respond to immunotherapy [44–48] suggests that
the immune system can generate antitumor reactivity under
speciﬁc circumstances [41, 49].
DCs are extremely potent antigen-presenting cells spe-
cialized in inducing activation and proliferation of lympho-
cytes,whichareessentialfortumorkilling[50].Patient’sown
DCs can be used to present tumor-associated antigens and
thereby generate tumor-speciﬁc immunity [3, 4]. Previously
we used the mesothelioma mouse model to examine the
impact of dendritic cell immunotherapy [5]. For malignant
mesothelioma, as for most other cancer types, only a
few tumor-associated antigens (TAAs) are known. These
antigens are not expressed on the membranes of all tumors
and therefore less suitable for antigen source for DC pulsing.
Furthermore, none of these TAAs have been evaluated as
a source of peptides to pulse DC or in a cancer vaccine
trial. Tumor lysate priming strategies are advantageous in
providing the full antigenic repertoire of the tumor and,
particularly, unique individual tumor antigens, which will
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Figure 5: Long-period administration of CTX improves survival
compared to pre- or post-immunotherapy treatment. Mice were
divided into four groups (n = 6 per group) and inoculated with
a lethal dose of AB1 tumor cells on day 0. Mice received low-dose
CTX before (day 3 till 10) or after (day 14 till 21) immunotherapy
or metronomic dosed CTX (day 3 till 10 and day 14 till 21).
Groups 2, 3, and 4 were treated with DC-immunotherapy on day
12. Group 1 functioned as a tumor control group and did not
receive any treatment. Administration of metronomic dosed CTX
was not signiﬁcantly better than CTX treatment before (P = .840)
or after (P = .454) immunotherapy. However, the combination
of CTX and immunotherapy was signiﬁcantly better than no
treatment (CTX before immunotherapy compared to untreated
P = .0081, CTX after immunotherapy compared to untreated
P = .0147, metronomic dosed CTX and immunotherapy compared
to untreated P = .0018).
theoretically decrease the ability of tumors to evade the
immune response by downregulation of a single antigen.
Therefore, DCs were pulsed with autologous total tumor
lysate fractions prepared by freeze thawing and sonication
of AB1 tumor cells. Mice receiving tumor lysate-loaded DCs
developed a protective antitumor immunity when animals
were vaccinated before tumor inoculation. They showed no
signsoftumorgrowthevenafter3monthsandafterrepeated
injection of tumor cells (2nd tumor challenge). MM had
a better outcome when DCs were injected early in tumor
developmentindicatingthattumorloadplayedanimportant
role in survival.
There are multiple levels to explain the limited beneﬁt
from DC vaccinations in mice with high tumor load. It has
been suggested that immune suppression by tumor-derived
factors is one of the main reasons for immunotherapy
failureingeneral[7,51].Tumorsescapeimmunerecognition
by attracting immune suppressive cells like Treg cells and
myeloid-derived suppressor cells. Others and we have shown
that mesothelioma cells are potent sources of a number
of cytokines (e.g., IL-6, IL-8, VEGF, GRO, and RANTES)
that might directly suppress immune activating cells, like
DCs and/or recruit suppressive cells and thereby abolish an
eﬃc i e n ti m m u n er e s p o n s e[ 8]. It has become evident that
while protecting the host against cancer development, the
immune cells also promote the emergence of tumors with
reduced immunogenicity leading to a complex interplay of
tumor growth and tumor regression mechanisms.8 Journal of Biomedicine and Biotechnology
Like in human mesothelioma biopsies, a growing
AB1 tumor in vivo contains signiﬁcant amounts of
CD4+CD25+Foxp3+ regulatoryTcells,whichwerepreviously
shown to promote tumor progression in other cancer
models. Exact mechanisms are not yet fully understood;
however one of the mechanisms by which Tregs can abolish
the eﬀectiveness of immunotherapy may be by their capacity
to produce granzyme B. This can lead to killing of cytotoxic
T cells [52–54]. Depletion of Tregs by using a blocking anti-
CD25 antibody (PC61), capable of speciﬁcally binding to the
IL-2 receptor α-chain, led to an increased survival in mice;
however, this depleting antibody is not suitable for human
clinical use. Cyclophosphamide (CTX) is an alkylating
cytotoxic cancer drug that, depending on its dose and timing
of administration, has been used as a chemotherapeutic and
disease-modifying agent or to enhance immune responses
[14, 26, 27, 55–57]. Reports dating from the 1980s have
shownthatundersomeconditionslow-doseCTXcanpoten-
tiate antitumor immunity in mouse models [55]. Recently it
has been suggested that this eﬀect is caused by the depletion
of Tregs [39]. Reductions in the amount of Tregs by using
CTX were also found in mesothelioma [28]. In addition, Van
der Most et al. showed that the combination of CTX and
gemcitabine eradicates established murine mesothelioma
whereas single treatment with gemcitabine did not lead
to total tumor regression [29]. However the beneﬁt of
combining Treg depletion with DC-based immunotherapy
for mesothelioma was not established till now.
CD4+CD25+Foxp3+ regulatory T cells comprise between
5and10%ofthetotalCD4+ populationinthebloodofmice,
and are important in controlling tolerance to self-antigens
and thereby maintain immune system homeostasis [54, 58].
We found that the prevalence of Tregs increases in tumor-
bearing mice in the tumor, peripheral blood, and lymph
nodes (Figures 1 and 3) as compared with normal controls.
Prolonged,lower-dose(“metronomic”)CTXinhibitstherise
of Tregs (Figure 3). This eﬀect augments the eﬃcacy of
dendritic cell-based immunotherapy (Figures 4 and 5). DC-
based immunotherapy leads to an increase in survival that is
further improved by depleting Treg cells.
5. Conclusion
We found that CTX is an applicable agent to reduce the
proportion of Tregs in tumor-bearing mice. In addition, we
showedthatcombiningCTXandDC-basedimmunotherapy
signiﬁcantly prolongs the mean and overall survival in
murine model for mesothelioma. We anticipate that CTX
allows the host immune system to overcome the immuno-
suppressive mechanisms of Tregs, thereby allowing for a
more complete and robust antitumor immune response
initiated by DC-vaccination that is paramount to eliminate
the tumor in vivo. Our ﬁndings suggest that CTX may also
potentiate the immunogenicity of DC-immunotherapy in
mesothelioma patients. In fact, these ﬁndings now form
the basis of a new trial aiming the depletion of Tregs by
CTX in combination with DC-based immunotherapy as
a multimodality treatment in mesothelioma patients after
chemotherapy.
Non-Standard Abbreviations
CTL(s): Cytotoxic T lymphocyte(s)
CTX: Cyclophosphamide
MM: Malignant mesothelioma
DC(s): Dendritic cell(s)
Treg(s): Regulatory T cell(s).
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